Report cover image

Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 190 Pages
SKU # IRE18313288

Description

Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2023-2030


The Biosimilars Market is projected to reach USD 176.48 billion by 2030 from USD 33.27 billion in 2022, at a CAGR of 23.18% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biosimilars Market.
  • Based on Product, market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon. The Recombinant Glycosylated Proteins is projected to witness significant market share during forecast period.
  • Based on Indication, market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology. The Chronic Diseases is projected to witness significant market share during forecast period.
  • Based on Manufacturing, market is studied across Contract Manufacturing and In-House Manufacturing. The Contract Manufacturing is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Biosimilars Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Biosimilars Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Biosimilars Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Biosimilars Market?
  3. What is the competitive strategic window for identifying opportunities in the Biosimilars Market?
  4. What are the latest technology trends and regulatory frameworks in the Biosimilars Market?
  5. What is the market share of the leading vendors in the Biosimilars Market?
  6. Which modes and strategic moves are suitable for entering the Biosimilars Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

190 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biosimilars Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.3. Opportunities
5.1.3.1. Improvements in biosimilar production processes
5.1.3.2. Supportive government initiative to develop biosimilars
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and laws
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
5.10.1. Technical Development & Trends
5.10.2. Regulatory Submissions Timelines
5.10.3. Clinical Bio Analytics and Technical Timelines and Related FTEs
5.10.4. Drugs Loosing Patent: 2018-2022
6. Biosimilars Market, by Product
6.1. Introduction
6.2. Recombinant Glycosylated Proteins
6.3.1. Erythropoietin
6.3.2. Follitropin
6.3.3. Monoclonal Antibodies
6.3.4.1. Adalimumab
6.3.4.2. Infliximab
6.3.4.3. Rituximab
6.3. Recombinant Non-Glycosylated Proteins
6.4.1. Granulocyte Colony-Stimulating Factor
6.4.2. Insulin
6.4.3. Interferons
6.4.4.1. Interferon-Alpha
6.4.4.2. Interferon-Beta
6.4.4. Recombinant Human Growth Hormone
6.4. Recombinant Peptides
6.5.1. Calcitonin
6.5.2. Glucagon
7. Biosimilars Market, by Indication
7.1. Introduction
7.2. Autoimmune Diseases
7.3. Blood Disorders
7.4. Chronic Diseases
7.5. Growth Hormone Deficiency
7.6. Infectious Diseases
7.7. Oncology
8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing
9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Alvotech
13.1.2. Amgen Inc.
13.1.3. Apotex Inc.
13.1.4. Biocon Limited
13.1.5. BioFactura, Inc.
13.1.6. Biogen Inc.
13.1.7. Boehringer Ingelheim International GmbH.
13.1.8. Catalent, Inc
13.1.9. Celltrion Healthcare Co.,Ltd.
13.1.10. Coherus BioSciences
13.1.11. Dr. Reddy's Laboratories Limited
13.1.12. Eden Biologics, Inc.
13.1.13. F. Hoffmann-La Roche AG
13.1.14. Fresenius Kabi
13.1.15. Innovent Biologics, Inc.
13.1.16. Intas Pharmaceuticals Ltd.
13.1.17. Kashiv BioSciences, LLC.
13.1.18. Merck & Co., Inc.
13.1.19. NeuClone
13.1.20. Nippon Kayaku Co., Ltd.
13.1.21. Novartis AG
13.1.22. Panacea Biotec Limited
13.1.23. Pfizer Inc.
13.1.24. Samsung Bioepis Co., Ltd.
13.1.25. Sanofi S.A.
13.1.26. Shanghai Henlius Biotech, Inc.
13.1.27. Teva Pharmaceutical Industries Ltd.
13.1.28. Thermo Fisher Scientific, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us